Sam Fazeli

Josh Schimmer × Eric Schmidt × Tess Cameron × Sam Fazeli

XBI’s rise into the mid-150s is backed by fundamentals, though an AI reversal could create cross-sector downside risk.Josh Schimmer’s regression found an R² of just 0.2 between XBI performance and deal value; AbbVie’s $10.9B Apogee purchase instead highlights replicability and order of entry.FDA normalization and continued China-originated financings are catalysts, while restrictions that compress biotech returns remain a risk.

Graig Suvannavejh × Josh Schimmer × Yaron Werber × Sam Fazeli × Oliver Barnes

XBI has rebounded 84% from its Liberation Day low to a fresh 52-week high, with financing and IPO activity pointing to improving risk appetite.Merck’s $6.7B Terns deal shows updated data can erase bidding leverage, while Gilead’s $3.15B Tubulis acquisition backs a differentiated ADC platform; Replimune’s second CRL leaves the FDA’s bar unclear, and obesity pricing competition remains a catalyst.

Eric Schmidt × Paul Matteis × Sam Fazeli × Graig Suvannavejh × Luba Greenwood

Graig Suvannavejh’s 15-year Sentometer shifted from record small-cap enthusiasm to “winter is coming,” pointing to probably another three months before biotech sentiment bottoms.Profitability is approaching across SMID biotech, but its value depends on reinvestment-driven growth, not modest earnings.SpringWorks’ expected Merck KGaA catalyst and Moderna’s cancer-vaccine timeline lead the watchlist, while FDA and NIH changes remain unresolved risks.

Josh Schimmer × Sam Fazeli × Brian Skorney × Yaron Werber × John Crowley

BIO CEO John Crowley says rising US trial costs and regulatory uncertainty make capital flowing to China “perfectly rational.”His FDA prescription—stability, consistency, transparency, and modernization—puts “the next 6 months” in focus.MFN codification could be “devastating” and “unmanageable” before Section 232 action due by the last week of March, while ReGenix’s PLAG1 integration tests AAV safety.

Eric Schmidt × Yaron Werber × Tess Cameron × Sam Fazeli

Biotech M&A is setting records across stages: Alkermes appears to have won Avadel at $2.4B, while J&J paid $3B for Phase 1 Halda, the highest-priced Phase 1 acquisition ever per Tess Cameron.Competition is intensifying as pharma prices in 2026-27 patent cliffs, but 82% of surveyed companies worry about FDA function; early-program delays could last two or three years, while falling drug prices make volume response a key watchpoint.

Daphne Zohar × Josh Schimmer × Brian Skorney × Paul Matteis × Sam Fazeli × Brad Loncar × Matt Gline

Trump’s letters to 17 pharma CEOs make MFN a risk, though no statutory authority was cited and implementation remains discounted.Medicaid and direct-to-consumer pricing may be easier; tougher IRA negotiations remain possible around September 29.GSK–Hengrui’s Phase 1 options and China’s 30% share of global trial starts sharpen outsourcing concerns; AHEAD’s 85%–90% screen-failure rate remains unresolved.

Eric Schmidt × Paul Matteis × Sam Fazeli × Brian Skorney

Elevidys escalated from restructuring to an FDA-requested, then accepted, full shipment halt after a third death, exposing regulatory, disclosure, debt, and political risks for Sarepta.Replimune’s RP1 delivered low-30s ORR with roughly half complete responses versus single-digit standard-of-care rates but received a CRL over its single-arm study, while Tidmarsh’s industry background and shifting FDA signals leave approval flexibility and small-biotech capital costs unresolved.

Josh Schimmer × Chris Garabedian × Sam Fazeli × Yaron Werber × Adam Feuerstein

Sarepta’s credibility crisis deepened after reporters disclosed a patient death tied to the rAAVrh74 vector, prompting FDA to request halting all Elevidys shipments and a trading halt.Ultragenyx’s CMC-only CRL and GSK’s failed Blenrep ODAC votes signal tighter scrutiny, while large-biopharma M&A and FDA encouragement leave catalysts alongside governance and regulatory risks.

Sam Fazeli × John Maraganore × Nina Kjellson × Matt Gline

Monday's MFN order creates a 30-day voluntary period and 180 days of negotiations, with no government-scale implementation or US price pressure expected by end-2025.Because US pricing controllers generally prefer higher prices, MFN could raise ex-US prices and leave biotech underrepresented, while conditional $234B pledges, CMS's 2028 subQ test, and CytomX's $100M financing provide catalysts.

Grace Colón × Josh Schimmer × Sam Fazeli × Tess Cameron × Eric Schmidt × Yaron Werber

Vinay Prasad’s CBER appointment erased 7% from XBI in a day, but his conciliatory debut shifted the key signal from rhetoric to approvals.MRD as a myeloma filing endpoint is the live test: a reversal could lengthen cell-therapy trials, while CDER bispecifics may retain it.Sarepta’s guidance cut to $2.3–2.6B exposed capacity risk, while Novavax and a possible MFN order leave regulatory and pricing catalysts unresolved.